

Name of the Issuer:		Rainbow Childrens Medicare Limited	Last updated on	16-Aug-23
<b>1</b>	<b>Type of Issue (IPO / FPO)</b>	IPO		
	Source: Prospectus dated April 29, 2022			
<b>2</b>	<b>Issue Size (Rs. Million)*</b>	<b>15,808.49</b>		
	- Fresh Issue Size (Rs. Millions)	2,800.00		
	- Offer for Sale Component (Rs. Millions)	13,008.49		
	*Source: Final post issue report dated May 12, 2022			
<b>3</b>	<b>Grade of issue along with name of the rating agency</b>			
	<b>Name</b>	Not Applicable		
	<b>Grade</b>	Not Applicable		
	Source: Prospectus dated April 29, 2022			
<b>4</b>	<b>Subscription Level (Number of times)</b>	<b>8.82999*</b>		
	*Source: Final post issue report dated May 12, 2022			
	*The above figure is after technical rejections			
<b>5</b>	<b>QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges</b>			
	<b>Particulars</b>	<b>%</b>		
	(i) allotment in the issue <sup>(1)</sup>	7.46%		
	(ii) at the end of 1st Quarter immediately after the listing* (June 30, 2022)	17.68%		
	(iii) at the end of 1st FY (March 31, 2023)	35.20%		
	(iv) at the end of 2nd FY (March 31, 2024)*	Not Available		
	(v) at the end of 3rd FY (March 31, 2025)*	Not Available		
	*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.			
	(1) Source: Institutions holding as disclosed in Stock exchange filing			

#### 6 Financials of the issuer

Parameters	(In Rs. Millions)		
	1st FY (March 31, 2023)	2nd FY (March 31, 2024)*	3rd FY (March 31, 2025)*
Income from Operations	11,735.74	Not Available	Not Available
Net Profit for the period	694.02	Not Available	Not Available
Paid-up equity share capital	1,015.02	Not Available	Not Available
Reserves excluding revaluation reserves	9,868.86	Not Available	Not Available
*Financials not disclosed as reporting for the relevant fiscal year has not been completed.			

#### 7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited  
The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2023)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2024)*	Not Available
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available

\*Trading status not disclosed as the relevant fiscal year has not been completed.

#### 8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2023)	Nil	Nil
(ii) at the end of 2nd FY (March 31, 2024)	Mr Anil Dhawan	Appointed
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available	Not Available

\* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

---

**9 Status of implementation of project/ commencement of commercial production**

- (i) as disclosed in the offer document      Not Applicable
- (ii) Actual implementation      Not Applicable
- (iii) Reasons for delay in implementation, if any      Not applicable

---

**10 Status of utilization of issue proceeds**

(i) As disclosed in the offer document

<b>Expenditure Item</b>	<b>Rs. Mn</b>
<i>Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited ("CDCEML"), one of our Group Companies, in full</i>	400.00
<i>Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals</i>	1,700.00
<i>General corporate purposes</i>	561.40

Source: Prospectus

(ii) Actual utilization

<b>Expenditure Item</b>	<b>Rs. Mn</b>
<i>Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited ("CDCEML"), one of our Group Companies, in full</i>	400.00
<i>Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals</i>	553.10
<i>General corporate purposes</i>	508.30

- (iii) Reasons for deviation, if any      Not Applicable.

---

**11 Comments of monitoring agency**

(a) Comments on use of funds	Not Applicable.
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

---

**12 Pricing Data**

Issue Price (Rs.):      542  
Designated Stock Exchange:      NSE  
Listing Date:      10-May-22

Price parameters	At close of listing day (May 10, 2022)	At close of 30th calendar day from listing day (June 08, 2022) <sup>(1)</sup>	At close of 90th calendar day from listing day (August 06, 2022) <sup>(2)(3)(4)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2023) <sup>(3)(4)</sup>		
				Closing price	High	Low
Market Price on Designated Stock Exchange <sup>(5)</sup>	450.20	467.00	472.60	730.50	739.00	723.60
NIFTY 50 <sup>(5)</sup>	16,240.05	16,356.25	17,397.50	17,359.75	18,812.50	15,293.50
Nifty Healthcare Index <sup>(6)</sup>	7,779.30	7,651.25	8,135.65	7,621.55	7,661.40	7,578.85

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2024) <sup>(3)(4)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2025) <sup>(3)(4)</sup>		
	Closing price	High	Low	Closing price	High	Low
Market Price on Designated Stock Exchange <sup>(5)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 <sup>(5)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty Healthcare Index <sup>(6)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

Source: NSE website

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant period/ fiscal year has not completed

(5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.

(6) Comparable Sectoral index is not available

### 13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2023)	At the end of 2nd FY (March 31, 2024) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2025) <sup>(2)</sup>
EPS	<b>Issuer:</b>			
	Consolidated (Basic)	4.36	20.89	Not Available
	Consolidated (Diluted)	4.25	20.89	Not Available
	<b>Peer Group: (Diluted)</b>			
	Apollo Hospitals Enterprise Limited	10.74	56.97	Not Available
	Fortis Healthcare Limited	-1.45	7.80	Not Available
	Narayana Hrudalaya Limited	-0.70	13.08	Not Available
	Max Healthcare Institute Limited	-1.59	7.16	Not Available
	Krishna Institute of Medical Sciences Limited	26.42	42.03	Not Available
	<b>Industry Avg:</b>	<b>6.68</b>	<b>25.41</b>	<b>N.A.</b>
Price to Earnings Ratio (P/E)	<b>Issuer:</b>			
	Consolidated (Basic)	124.31	34.97	Not Available
	Consolidated (Diluted)	127.53	34.97	Not Available
	<b>Peer Group (Consolidated)</b>			
	Apollo Hospitals Enterprise Limited	428.88	75.64	Not Available
	Fortis Healthcare Limited	N.A. since EPS is negative	33.33	Not Available
	Narayana Hrudalaya Limited	N.A. since EPS is negative	59.18	Not Available
	Max Healthcare Institute Limited	N.A. since EPS is negative	61.59	Not Available

	Krishna Institute of Medical Sciences Limited	54.19	33.46	Not Available	Not Available
	<b>Industry Avg:</b>	<b>241.54</b>	<b>52.64</b>	<b>N.A.</b>	<b>N.A.</b>
RoNW(%)	<b>Issuer:</b>				
	Consolidated	8.88%	6.38%	Not Available	Not Available
	<b>Peer Group: (Consolidated)</b>				
	Apollo Hospitals Enterprise Limited	3.30%	13.65%	Not Available	Not Available
	Fortis Healthcare Limited	-0.75%	8.74%	Not Available	Not Available
	Narayana Hrudalaya Limited	-1.46%	18.09%	Not Available	Not Available
	Max Healthcare Institute Limited	-2.47%	9.86%	Not Available	Not Available
	Krishna Institute of Medical Sciences Limited	23.74%	15.12%	Not Available	Not Available
	<b>Industry Avg:</b>	<b>4.47%</b>	<b>13.09%</b>	<b>N.A.</b>	<b>N.A.</b>
NAV per Equity Share	<b>Issuer:</b>				
	Consolidated	86.07	213.73	Not Available	Not Available
	<b>Peer Group: (Consolidated)</b>				
	Apollo Hospitals Enterprise Limited	320.1	43.05	Not Available	Not Available
	Fortis Healthcare Limited	81.06	9.59	Not Available	Not Available
	Narayana Hrudalaya Limited	54.82	7.19	Not Available	Not Available
	Max Healthcare Institute Limited	58.37	7.25	Not Available	Not Available
	Krishna Institute of Medical Sciences Limited	111.32	208.62	Not Available	Not Available
	<b>Industry Avg:</b>	<b>125.13</b>	<b>55.14</b>	<b>N.A.</b>	<b>N.A.</b>

<b>Notes:</b>					
(1) Sourced from Prospectus dated May 2, 2022.					
(2) Information not provided as the relevant fiscal year has not completed					
Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:					
(i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the fiscal year.					
Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015					
(ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable for equity shareholders (after adjusting profit impact of dilutive potential equity shares, if any) / the aggregate of weighted average number of Equity shares outstanding during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive					
(iii) Total Income = Revenue from Operations and Other Income					
(iv) P/E (Basic/Diluted) - Closing Market Price at the end of relevant fiscal year end on BSE/ Basic/Diluted EPS					
(v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year.					
(vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year./ Number of equity shares outstanding as at the end of fiscal year					

#### 14 Any other material information

Date of disclosure	Announcement
27-May-22	Company has informed the Exchange that the Board of Directors in their meeting held on May 27, 2022 approved following matters:1. The Audited Standalone and Consolidated Financial Results ("Results") of the Company for the Quarter and Financial Year ended March 31, 2022. 2. Recommendation of final dividend of INR. 2.0/- per Equity Share (@ 20% on a face value of INR. 10/- per share) for the Financial Year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting ("AGM") will be dispatched/ credited within 30 days of the AGM and further information in this regard including record date etc. shall be submitted with the Stock Exchanges in due course
9-Jun-22	Submission of Disclosures of Related Party Transactions for the half year ended 31st March, 2022 pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021
10-Jun-22	Company has informed the Exchanges that pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, Dr. Rohit Manipal Bhojaraj, Group Chief Operating Officer, has tendered his resignation owing to personal reasons, the company has accepted his resignation, which will be effective from close of business hours on June 15, 2022.The handing over process is underway and the company has already initiated the process to identify a replacement.In the interim, till a replacement assumes the role, Dr. Ramesh Kancharla, Chairman and Managing Director and Dr. Dinesh Kumar Chirla, Whole Time Director, would be handling the responsibilities of the Group Chief Operating Officer and there would be no disruption in the functioning of the organization.We request you to kindly take the same on record.

8-Aug-22	Rainbow Children's Medicare Limited has informed the Exchange about :1. The unaudited Standalone and Consolidated Financial Results ("Results") of the Company for the first Quarter ended June 30, 2022. Copies of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith. 2. Convening of 24th Annual General Meeting ("AGM") of the Company on Thursday September 15, 2022 through Video Conferencing/ Other Audio Visual Means (VC/OVAM).3. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders at the ensuing AGM).4. Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM. The details of the reclassification of Authorised Share Capital is described below:→Reclassification of Authorized Share Capital from INR. 150,00,00,000 divided into (a) 13,90,55,616 Equity Shares of INR 10/- each (b) 11,46,771 - Series A 0.0001% Compulsorily Convertible Preference Shares ("Series A CCPS") of INR. 48/- each and (c) 11,33,309 Series B 0.0001% Compulsorily Convertible Preference Shares ("Series B CCPS") of INR. 48/- to INR. 150,00,00,000 divided into 15,00,00,000 Equity Shares of INR 10/- each.
8-Aug-22	Rainbow Children s Medicare Limited has informed the Exchange that Record date for the purpose of Final Dividend for Financial Year 2021-22 as September 8, 2022
29-Aug-22	Rainbow Children's Medicare Limited (Rainbow/Company) on August 29, 2022 has inaugurated a new 55-beds spoke hospital, located at OMR (Sholinganallur) at Chennai. This is Rainbow's first spoke hospital in Chennai. The hospital isdesigned to provide comprehensive pediatric and obstetrics services. The Company is already operating a 135- beds hub hospital at Guindy, Chennai, Tamil Nadu
1-Mar-23	Commencement of a new 100 bed spoke hospital at Financial District, Hyderabad,Telangana.
15-Apr-23	Appointment of Mr Sanjeev Sukumaran as Group Chief Operating Officer (KMP) of the company w.e.f. April 15, 2023.
14-May-23	Appointment of Mr Anil Dhawan as Non- Executive Independent Director of the company w.e.f. August 30, 2023
14-May-23	Appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 101049W/ E300004) as the Statutory Auditors of the Company'. for a period of five years commencing from the conclusion of ensuing 25th Annual General Meeting till the conclusion of 30th Annual General Meeting of the Company, subject to approval of the Shareholders in the ensuing 25th Annual General Meeting (in place of the retiring Auditors M/s. BSR & Associates LLP, Chartered Accountants
31-May-23	Resignation of Mr R Gowrisankar as Chief Financial Officer of the company w.e.f. May 31, 2023
5-Jul-23	Receipt of allotment letter from HSVP, for the allotment of land parcels located in Sector 44 & Sector 56 of Gurugram, Haryana.

Source: BSE / NSE website

**Note:** The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com).